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Methods: Patients (n 5 2042) with mild and moderate AD were randomized 1:1 to 400-mg
solanezumab or placebo infusion every 4 weeks for 80 weeks and 1457 patients entered an open-
label extension. Magnetic resonance imaging scans monitored for amyloid-related imaging
abnormalities-edema/effusion (ARIA-E) and amyloid-related imaging abnormalities-hemorrhage/
hemosiderin deposition.
Results: Sixteen patients (solanezumab, n 5 11; placebo, n 5 5) developed ARIA-E during the
double-blind phase, and 7 patients developed ARIA-E during the open-label extension as of July
31, 2014. Unique cases are discussed including solanezumab patients who were given solanezumab,
while ARIA-E was present and a patient who developed ARIA-E during placebo treatment and again
during solanezumab treatment.
Discussion: Asymptomatic ARIA-E was detected in solanezumab-treated and placebo-treated AD
patients. ARIA-E occurs infrequently during solanezumab and placebo treatments but may occur
repeatedly in some patients.
 2016 Eli Lilly and Company. Published by Elsevier Inc. on behalf of the Alzheimer’s Association.
This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Keywords: Amyloid-related imaging abnormalities; Alzheimer’s disease; Clinical trials1. Introduction
Magnetic resonance imaging (MRI) scans obtained during
clinical trials in Alzheimer’s disease (AD) patients have iden-
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imaging abnormality hemorrhage/hemosiderin deposition
(ARIA-H) [1]. ARIA-E appears as a hyperintensity in fluid-
attenuated inversion recovery imaging (FLAIR) sequences
and is due to parenchymal fluid accumulation (edema) or sul-
cal fluid effusion. ARIA-H appears as focal, round, or linear
signal voids in T2*-weighted gradient recalled echo (GRE)
sequences due to the iron content of residual hemosiderin
deposition [1]. ARIA was initially thought to result from
amyloid removal from the brain after treatment with anti-
amyloid agents [1]. Subsequently, ARIA-E was found at
baseline in 0.1% of untreated AD patients in two phase 3
studies of solanezumab and two phase 3 studies ofthe Alzheimer’s Association. This is an open access article under the CCBY-
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view of baseline scans from three bapineuzumab studies [3].
Microhemorrhage was observed in a natural history study of
memory clinic patients with a prevalence of 19%–24% and a
2-year incidence of 12% [4]. ARIA-E [3,5–8] and both
ARIA-E and ARIA-H [3,7,8] abnormalities have been
reported during treatment of AD patients with anti-amyloid
antibodies, but ARIA-E has also occurred during placebo
treatment [3,6,8]. ARIA-E is generally transient, reversible,
and in milder cases, it may be clinically asymptomatic
[3,5–8]. The clinical impact of ARIA is a variable
depending on severity and location; ARIA-E may have con-
current symptoms such as headache, mental state changes,
confusion, gait disturbances, tremor, vomiting, and/or nausea
[3,5,7] and may require intervention beyond withholding
treatment to address concomitant symptoms [5].
This article focuses on ARIA-E cases from two
completed, double-blind, randomized studies [8] and one
ongoing, open-label study of solanezumab in patients with
mild-to-moderate AD. The limited number of cases high-
lights the variable and dynamic aspects of ARIA-E with
both static and changing areas of edema and a wide range
for time to onset and resolution in both placebo (PBO) and
solanezumab (SLZ) treatment groups. Case studies were
selected based on their ability to address several important
clinical aspects of ARIA-E and its implications on treatment.
All cases in these trials were asymptomatic.2. Methods
Data were obtained from two completed double-blind tri-
als (EXPEDITION and EXPEDITION 2) and their ongoing
open-label extension trial (EXPEDITION-EXT, data up to
July 31, 2014) of solanezumab for the treatment of mild-
to-moderate AD. The specific details of the double-blind
trials and baseline demographics have been described previ-
ously [8]. MRIs were obtained at baseline, endpoint and at
scheduled visits. Unscheduled MRIs were obtained any
time at the discretion of the investigator.
MRIs were assessed centrally by trained and validated
neurologists. The neurologists are board certified and
licensed physicians with subspecialty board certification in
Radiology by the American Board of Radiology and spe-
cialty training in Neuroradiology with Certificates of Added
Qualification in Neuroradiology, granted by the American
Board of Radiology. The readers have been the central
readers for the evaluation of ARIA on an average of 30 Alz-
heimer’s trials each.
FLAIR sequences were evaluated for the presence of
ARIA-E presenting either within the brain parenchyma or
as sulcal FLAIR hyperintensity. ARIA-E severity was char-
acterized as mild (confined to focal area), moderate (nonfo-
cal, involving more than one site), and severe (multi-site,
with extensive areas of involvement). When ARIA-E was
detected, infusions were held unless otherwise noted, and
follow-up MRIs were suggested at 4–6-week intervals.GRE sequences were obtained and evaluated for the pres-
ence of ARIA-H. Patients were not excluded due to the pres-
ence of ARIA-H in most countries except for the United
Kingdom and France where patients with .2 ARIA-H
were excluded. ARIA-H were counted and reported as cate-
gories 0, 1, 2 to 5, 6 to 10 and.10, according to the number
of ARIA-H seen. Co-localization of ARIA-E and ARIA-H
was defined as occurrence or development of both in similar
locations (within approximately 1 cm) in relatively similar
time frames, although development may be separated
temporally.
MRI was obtained at 221 imaging centers across 16 coun-
tries for which MRI standardization training was performed.
Imaging was conducted on platforms including three MRI
vendors (Siemens, General Electric, and Philips) and MRI
field strengths of 1.5 or 3.0 Tesla [2]. 2D FLAIR protocol
was harmonized across manufacturers and field strength
with range of values: Echo Time 5 94–140 ms; inversion
time 5 2200–2800 ms; repetition time 5 9000–10000 ms;
slice thickness 5 5 mm with 1 mm gap [2].
The percentages of patients with ARIA-E and ARIA-H
were compared between treatment groups in EXPEDITION
and EXPEDITION 2 using a Cochran-Mantel Haenszel test
for general association controlling for study. For patients
originally assigned to placebo during the double-blind
studies, the entire observation period was reported; however,
when they developed ARIA-E during solanezumab treat-
ment in the open-label study, they were considered as
solanezumab-treated patients. Final MRI outcome was
determined using the last available MRI obtained. Some pa-
tients may have continued infusions without scheduled
or unscheduled MRIs. Therefore, if ARIA-E did occur, it
was not associated with any symptoms. As some analyses
were conducted on data from patients in the ongoing study
EXPEDITION-EXT, changes in some data may occur on
subsequent final data lock.3. Results
Two cases of ARIA-E were detected during screening of
patients for the double-blind studies EXPEDITION and
EXPEDITION 2, and these patients were excluded from
the studies [2]. During the double-blind treatment period,
ARIA-E occurred in both placebo- (PBO, n 5 5) and
solanezumab-treated patients (SLZ, n 5 11; P 5 .131;
Table 1). Seven cases occurred during the open-label study
EXPEDITION-EXT, with one patient, Patient B, in both
groups (Table 1). There was a mix of sulcal (nine instances)
and parenchymal (13 instances) and mixed sulcal and paren-
chymal (one instance) ARIA-E (Table 1). Adverse events
were reviewed for events preceding detection of and during
ARIA-E, and all cases were asymptomatic. One patient (C)
reported a headache and nausea approximately 1 month
before the scheduled MRI and again 2 days after the sched-
uled MRI showed ARIA-E. However, the headache and
nausea resolved each time within 48 hours after treatment
Table 1
ARIA E summary table
Patient ID
Original
treatment
assignment
in EXP 1/2
Baseline severity
(Visit 1 MMSE)
Age at consent
into feeder
study (y)
APOE
genotype
Relative
onset
(days)*
ARIA-E
Sulcal and/or
Parenchymal
Maximum
ARIA-E
severity
ARIA-H at
baseline
ARIA-H at
time of
ARIA-E
MRI Outcome/Last
observation
EXPEDITION
A PBO Mild 79 ε2/ε4 562 Sulcal Moderate 1 6 to 10y Complete resolution,
75 days
B PBO Mild 80 ε3/ε4 86 Sulcal Mild 0 0 Complete resolution,
36 days
C SLZ Mild 81 N/A 365 Parenchymal Moderate 6 to 10 .10 Partial resolution,
149 days (ED,
ARIA-E)
D SLZ Mild 73 ε3/ε4 366 Sulcal Mild 0 2 to 5y Complete resolution,
189 days
E SLZ Mild 80 ε3/ε3 428 Parenchymal Mild 6 to 10 .10 Complete resolution,
78 days
F SLZ Mild 67 ε4/ε4 561 Sulcal Severe 1 2 to 5y Partial resolution,
300 days (increased
ARIA-H to .10 at
discontinuation)
EXPEDITION 2
G PBO Moderate 69 ε4/ε4 361 Sulcal Moderate 2 to 5 .10y Partial resolution,
22 days (ED,
ARIA-H)
H PBO Mild 79 ε2/ε3 566 Parenchymal Mild 2 to 5 .10 Complete resolution,
661 daysz
I PBO Mild 70 ε4/ε4 73 Sulcal and
Parenchymal
Mild .10 .10 Partial resolution,
316 days (ED,
ARIA-E)
J SLZ Mild 93 ε2/ε3 370 Parenchymal Severe 0 N/A No change ARIA-E,
70 days (ED,
ARIA-E; Increased
ARIA-H to .10 at
discontinuation)
K SLZ Mild 72 N/A 22 Sulcal Moderate 1 2 to 5y Complete resolution,
227 days (ED,
ARIA-H increased
to 6–10)
L SLZ Mild 69 N/A 83 Sulcal Mild 2 to 5 2 to 5y Complete resolution,
73 days
M SLZ Mild 75 ε3/ε3 197 Parenchymal Mild .10 .10 (increased) Complete resolution,
54 days (ED)
N SLZ Mild 74 ε4/ε4 525 Parenchymal Moderate 0 1y Partial resolution,
51 days
O SLZ Moderate 66 ε3/ε4 361 Parenchymal Severe 0 6 to 10y
(Continued )
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Table 1
ARIA E summary table (Continued )
Patient ID
Original
treatment
assignment
in EXP 1/2
Baseline severity
(Visit 1 MMSE)
Age at consent
into feeder
study (y)
APOE
genotype
Relative
onset
(days)*
ARIA-E
Sulcal and/or
Parenchymal
Maximum
ARIA-E
severity
ARIA-H at
baseline
ARIA-H at
time of
ARIA-E
MRI Outcome/Last
observation
Increased ARIA-E,
127 days (ED,
ARIA-E)
P SLZ Moderatex 85 ε3/ε3 79 Parenchymal Mild 2 to 5 N/A Increased ARIA-E
and ARIA-H to
.10, 477 days
EXPEDITION-EXTk (All patients received open-label SLZ)
B PBO Mild 80 ε3/ε4 913 Sulcal Moderate 0 0 Complete resolution,
50 days
Q PBO Mild 84 ε3/ε4 915 Parenchymal Mild 0 .10 No change, 33 days
R PBO Mild 70 ε4/ε4 730 Sulcal Mild 0 2 to 5y Complete resolution,
29 days
S PBO Mild 72 ε4/ε4 1295 Parenchymal Mild 6 to 10 .10 Increased ARIA-E,
36 days
T SLZ Mild 84 ε3/ε3 1292 Parenchymal Moderate 0 0 No change, 32 days
U SLZ Moderate 78 ε2/ε3 1285 Parenchymal Mild 0 .10 No change, 22 days
(ED, ARIA-H)
V SLZ Mild 79 ε3/ε3 756 Parenchymal Mild 2 to 5 .10y Increased ARIA-E,
243 days (ED,
ARIA-E)
Abbreviations: ED, early discontinuation; MMSE, Mini-Mental State Examination; N/A, not available; PBO, placebo; SLZ, solanezumab.
*Relative onset (days) is calculated from date of first infusion in EXPEDITION or EXPEDITION 2.
yColocalization of new ARIA-H and ARIA-E.
zPatient H developed ARIA-E during PBO treatment in EXPEDITION 2 then initiated treatment with SLZ in EXPEDITION-EXT and ARIA-E resolved during SLZ treatment during EXPEDITION-EXT.
xPatient P had anMMSE score of 13 at visit 1, which was outside the inclusion and/or exclusion criteria for the study. At visit 2, Patient P had an MMSE score of 17 so is considered of moderate disease severity
for this analysis.
kTreatment during double-blind trial (all received SLZ in open-label trial). Relative onset of ARIA-E for patients treated with PBO in EXPEDITION and EXPEDITION 2 includes approximately 560 days of
observation in those studies.
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C. Carlson et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2 (2016) 75-85 79with paracetamol, whereas the ARIA-E was only partially
resolved at the last MRI obtained 149 days after the initial
observation.
In placebo-treated and solanezumab-treated patients,
ARIA-E occurred throughout the observation period with a
range of onset between 73–566 and 22–1295 days, respec-
tively (Table 1). The range for time to resolution and/or par-
tial resolution was also variable for placebo-treated and
solanezumab-treated patients, ranging from 22–316 and
51–300 days, respectively (Table 1). One patient (H) as-
signed to placebo in the feeder studies developed ARIA-E,
switched to open-label solanezumab for 14 infusions and
then stopped dosing; the patient then had complete resolu-
tion after an additional 303 days (661 days from onset).
Complete resolution was observed in 10 patients (three
PBO and seven SLZ) and partial resolution in 5 patients
(two PBO and three SLZ; Table 1). Some solanezumab-
treated patients had limited follow-up; four had no change,
and four had increased ARIA-E at the last MRI obtained
(Table 1).
In 19 of 22 of the ARIA-E patients, APOE genotype was
available. Eleven of 19 (58%) ARIA-E patients with APOE
genotyping were APOE ε4 carriers compared with 1098 of
1866 (59%) of the overall study population (Table 1). This
suggests that the APOE ε4 allele is not over represented in
the cohort of patients with ARIA-E. However, six of the
19 ARIA-E patients (32%) were APOE ε4 homozygotes
(Table 1), compared with 242 of 1866 (13%) of the overall
study population. This suggests that patients with two
APOE ε4 alleles are at increased risk of developing ARIA-E.
In the pooled trial population at baseline, 1639 of 2019
(approximately 80%) patients had no ARIA-H at baseline
(Fig. 1A). In addition, there were no significant differences
in the categorical distribution of ARIA-H between treatment
groups at baseline (Fig. 1). During the double-blind treat-
ment period, 7.3% and 9.1% of placebo and solanezumab-
treated patients had changes in ARIA-H, respectively
(P 5 .14). In addition, there was no significant difference
in the degree (number) of increases in ARIA-H between
the placebo and solanezumab treatment groups (P . .08;
Fig. 1B). At the time of ARIA-E detection, 3 of 23 patients
(one patient was counted twice) had no ARIA-H and in two
patients, ARIA-H status was not analyzable (Table 1).
Sixteen of 21 patients (76%) with ARIA-E and scans assess-
able for ARIA-H experienced increases in ARIA-H at the
time of ARIA-E (PBO, 3/5: 60% and SLZ, 13/16; 81%;
Table 1). In those 16 patients, 10 had co-localization of
ARIA-H changes with ARIA-E (Table 1).Fig. 1. (A) Baseline distribution of ARIA-H by treatment. ARIA-H was
categorized as 0, 1, 2 to 5, 6 to 10, and .10, (B) Categorical increases in
ARIA-H. Categorical increases were determined by the number of increases
between categories 1, 2 to 5, 6 to 10,.10, and. 10 with further increases.3.1. Summary of patients treated with solanezumab during
ARIA-E
Eight patients continued to be infused with solanezumab
during ARIA-E: Patient D, seven infusions, complete
resolution; Patient E, three infusions, complete resolution;
Patient H, 14 infusions during EXPEDITION-EXT, partialresolution at early discontinuation (ED) followed by com-
plete resolution 10 months after infusions were stopped; Pa-
tient K, two infusions followed by increased ARIA-E, two
additional infusions followed by partial resolution and
cessation of infusions at which point increased ARIA-E
was followed by complete resolution; Patient O, three infu-
sions, increased ARIA-E at ED; Patient P, 17 infusions,
increased ARIA-E at study end; Patient S, two infusions
during EXPEDITION-EXT, increased ARIA-E at ED; Pa-
tient T, one infusion during EXPEDITION-EXT, no change
at last available MRI. The infusions continued in some pa-
tients because ARIA-E was identified at a later time point
and retrospective review of prior scans showed ARIA-E
was initially not recognized and occurred earlier than orig-
inally thought. Other patients continued to be infused at the
investigator’s discretion. All patients remained asymptom-
atic during this time.3.2. Case 1—patient treated with solanezumab during
ARIA-E
Patient P, an 85-year-old male with APOE ε3/ε3 geno-
type, was treated with solanezumab.
C. Carlson et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2 (2016) 75-8580ARIA-E was first recognized at the Week 80 MRI
(endpoint), and prior MRIs were then retrospectively re-
viewed. The patient continued to be infused throughout the
study. Retrospective review of Week 12 MRI, 79 days after
randomization to solanezumab, identified mild left temporal
ARIA-E (Fig. 2A). ARIA-H was not assessable on that MRI
due to motion artifact during the GRE sequence.
Retrospective review of the Week 28 MRI, 198 days after
randomization and 120 days after the prior MRI, showed an
increase in ARIA-E evidenced by peripheral foci of T2 hy-
perintensity in the right parietal lobe (Fig. 2B). The left tem-
poral ARIA-E had resolved. ARIA-H had increased (from
category 2 to 5 to category 6 to 10) as a new punctate micro-
heme in the right occipital lobe.
Retrospective review of the Week 52 MRI, 359 days after
randomization and 281 days after the first appearance of
ARIA-E, showed that right parietal ARIA-E had resolved.
There was a very subtle new focus of FLAIR hyperintensity
in the right occipital lobe, which was most compatible with
mild ARIA-E (Fig. 2C). ARIA-H had increased to .10, as
several of the peripheral foci of T2 shortening, previously
felt to indicate normal vasculature, were now noted to indi-
cate microhemes.
The Week 80 (endpoint) MRI, 555 days after randomiza-
tion and 477 days after the first appearance of ARIA-E
showed increased mild ARIA-E in the right temporal and oc-
cipital lobes and increased size and number of ARIA-H
(category remained . 10; Fig. 2D). The patient completed
the study while remaining asymptomatic the entire time.
No further MRI follow-up was available.3.3. Summary of patients treated or rechallenged with
solanezumab after ARIA-E resolution
Four patients who developed ARIA-E, had infusions
stopped, and had complete resolution were then re-
challenged with solanezumab or began solanezumab treat-
ment after placebo treatment. Three of 4 patients had no
further occurrence overw1.5 to 2 years. After complete res-
olution of moderate ARIA-E while on placebo during
EXPEDITION, Patient A enrolled in EXPEDITION-EXTFig. 2. FLAIR images from patient P. (A) 12 weeks, (B) 28 weeks, (C)and had no additional ARIA-E during 2 years of solanezu-
mab infusions. After complete resolution of mild ARIA-E
while on placebo during EXPEDITION, Patient B enrolled
in EXPEDITION-EXT and moderate ARIA-E was detected
after 13 solanezumab infusions. After complete resolution of
this occurrence of ARIA, the patient was re-challenged, re-
mained in the study for an additional year and had no further
ARIA-E. Patient L was originally treated with solanezumab
during EXPEDITION 2 and had ARIA-E at Week 12 (four
infusions). After complete resolution of mild right and
left-frontal ARIA-E, the patient received an additional 14
solanezumab infusions in EXPEDITION 2 with no recur-
rence of ARIA-E. Patient L then enrolled in
EXPEDITION-EXT and discontinued after approximately
2 years and 8 months due to patient decision regarding
inability to tolerate further MRI without an another MRI
or incidence of symptomatic ARIA-E. Patient R enrolled
in EXPEDITION-EXT and developed ARIA-E after seven
infusions. Patient R restarted solanezumab after resolution
of ARIA-E and continued for another 18 infusions with no
additional incidence of ARIA-E. Infusions were stopped af-
ter ARIA-E was detected in the remaining two PBO and
eight solanezumab patients with ARIA-E (patients C, F, G,
I, J, M, N, Q, U, and V). These patients were not re-chal-
lenged.3.4. Case 2—patient with more than one occurrence
Patient B, an 80-year-old female with APOE ε3/ε4 geno-
type, was randomized to placebo.
The Week 12 MRI, 86 days after randomization, showed
mild cerebellar, left temporal, and left occipital lobe ARIA-
E with a focus of abnormal sulcal FLAIR hyperintensity
(Fig. 3A). No ARIA-H was detected at baseline or at the
time of ARIA-E. An unscheduled MRI after 36 days showed
complete resolution of ARIA-E (Fig. 3B) and study infu-
sions restarted. An unscheduled follow-up MRI, 21 days af-
ter resumption of study infusions, showed no reoccurrence
of ARIA-E. The patient completed the study without further
incidence of ARIA-E and enrolled into the open-label study
EXPEDITION-EXT.52 weeks, (D) 80 weeks. Red arrows indicate areas of ARIA-E.
Fig. 3. FLAIR images from patient B. EXPEDITION (A) 12 weeks, and
Unscheduled 1, 36 days; EXPEDITION-EXT (B) 52 weeks, and Unsched-
uled 1, 50 day. Arrows indicate areas of ARIA-E.
C. Carlson et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2 (2016) 75-85 81During EXPEDITION-EXT, the Week 52 MRI, 359 days
after beginning solanezumab treatment, showed moderate
sulcal right temporal and occipital ARIA-E (Fig. 3C). Again,
no ARIA-H was detected. An unscheduled MRI, after
50 days, showed ARIA-E had again completely resolved
(Fig. 3D). Patient was re-challenged with study drug and re-
mained in the study with no further ARIA-E.
3.5. Case 3—patient with increased ARIA-E on follow-up
MRIs after infusions held
Patient F, a 67 year old femalewith APOE ε4/ε4 genotype
was randomized to solanezumab.
The Week 80 MRI (endpoint) showed moderate sulcal
left temporal, left parietal, and bilateral occipital ARIA-E
(Fig. 4A) and increased ARIA-H from category 1 at baseline
to category 2 to 5. A thin linear macroheme (.1 cm in over-
all length) had also developed adjacent to the previously
seen left occipital microheme. The patient completed the
study; she did not enroll in EXPEDITION-EXT but
continued to be followed.
Unscheduled MRIs, after 85 days and 118 days, showed
increased ARIA-E (severe) and ARIA-H (to 6 to 10 and to
.10, respectively) (Fig. 4B and C). The next unscheduled
MRI, after 195 days, showed slight worsening of ARIA-E
in areas of left parietal subcortical white matter butimprovement in other areas; overall, ARIA-E had resolved
to moderate severity (Fig. 4D). The number of ARIA-H
was unchanged; however, a linear area of hemosiderin in
the right occipital lobe had slightly increased in size.
The fourth unscheduled MRI, after 258 days, showed
further partial resolution of ARIA-E (Fig. 4E). There
was residual ARIA-E primarily in the left parietal lobe
with mild involvement of the superior left occipital lobe,
and subtle residual left temporal lobe ARIA-E. ARIA-H
were unchanged. The final unscheduled MRI, after
300 days, showed further partial resolution of ARIA-E
to mild severity (Fig. 4F) and an increase in the number
and increased size of previously identified ARIA-H (cate-
gory remained . 10).
3.6. Case 4—placebo-treated patient with long follow-up
and time to partial resolution
Patient I was a 70-year-old female with APOE ε4/ε4 ge-
notype, treated with placebo.
The Week 12 MRI, 73 days after randomization,
showed mild sulcal and parenchymal right occipital
ARIA-E (Fig. 5A). Microhemes noted in this area at
screening remained unchanged. Infusions were stopped.
An unscheduled MRI, after 54 days, showed no significant
change in the ARIA-E (Fig. 5B) or ARIA-H. The next un-
scheduled MRI, after 93 days, showed additional ARIA-E
(Fig. 5C) and no change in the ARIA-H. The ED (due to
ARIA-E) visit MRI, after 168 days, showed no change in
ARIA-E (Fig. 5D) or ARIA-H. The final MRI, after
316 days, showed partial resolution of the ARIA-E
(Fig. 5E) and an increase in the number of ARIA-H to
category .10 with further increase. No further follow-up
was performed.
4. Discussion
In an earlier review of baseline scans from clinical trials of
patients with mild to moderate AD, ARIA-E was found to
occur at a very low prevalence of ,0.1%–0.8% in untreated
patients [2,3]. The incidence of ARIA-E is significantly
greater during treatment with some agents that target amyloid
compared with placebo-treated patients [3,5–7]. It is thought
that more ARIA is associated with treatment with anti-
amyloid antibodies such as bapineuzumab and gantenerumab
that target the N-terminal region of Ab because those epitopes
are exposed in amyloid plaques [9] and are available for anti-
body binding. It has been suggested that during bapineuzumab
treatment, parenchymal plaque is transiently relocated to the
cerebral vasculature [10,11] and either the increased
cerebrovascular amyloid or removal of amyloid in weakened
vasculature leads to ARIA-E and ARIA-H [1]. Solanezumab
binds to the mid-domain of Ab and does not bind deposited
amyloid plaque, presumably because this domain is unavai-
lable. Because solanezumab binds only soluble Ab with
very high affinity, it should not be associated with transloca-
tion of amyloid to or direct removal from the cerebral
Fig. 4. FLAIR images from patient F. (A) 80 weeks, (B) unscheduled 1, (C) unscheduled 2, (D) unscheduled 3, (E) unscheduled 4, (F) unscheduled 5. Red
arrows indicate areas of ARIA-E.
C. Carlson et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2 (2016) 75-8582vasculature and therefore be associated with less ARIA than
N-terminally directed antibodies that target deposited plaque.
ARIA inplacebo-treated subjectsmay occur fromothermech-
anisms such as disease-mediated changes in amyloid produc-
tion and/or clearance or local inflammatory processes [1].
In double-blind phase 3 trials of solanezumab, asymp-
tomatic ARIA-E occurred in placebo-treated patients
(0.5%) and solanezumab-treated patients (1.1%, P 5 .131;
Table 1). In both treatment groups, ARIA-E was a variable
dynamic process with a range of severity, sometimes occur-
ring in one or more brain regions. In placebo-treated and
solanezumab-treated patients, ARIA-E occurred with a
wide range of time to onset and time to resolution with
some patients having no change or increased ARIA-E at
their final study MRI. No cases were clearly related to
concomitant symptoms.Phase 2 studies of bapineuzumab have reported an inci-
dence of ARIA-E in treated patients of 9.7%, with a dose-
dependent increase in incidence of up to 26.7%, whereas
the incidence in placebo-treated patients was 0.8% [5]. In
a combined retrospective reanalysis of MRIs from the two
phase 2 studies and an open-label extension study of bapi-
neuzumab, 17% of bapineuzumab-treated patients had
ARIA-E with a dose-dependent increase in risk [3]. The
mean number of infusions (every 13 weeks) before detection
of ARIA-E was 2.4 (SD 1.7; range 1–7). Most ARIA-E cases
(25 of 36; 69%) were identified after the first or second infu-
sion. ARIA-Ewas not observed.2 years after the first expo-
sure to bapineuzumab. The median duration of ARIA-E for
the 31 of 36 patients whose ARIA-E was resolved on follow-
up scans was 113 days (IQR, 61–182) [3]. Phase 3 studies of
bapineuzumab have reported an incidence of ARIA-E in
Fig. 5. FLAIR images from patient I. (A) 12 weeks, (B) unscheduled 1, (C) unscheduled 2, (D) unscheduled 3 (ED), (E) unscheduled 4. Red arrows indicate
areas of ARIA-E.
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dependent increase in incidence of 14.2% in the 2.0-mg/kg
APOE ε4 noncarrier group and 15.3% in the 0.5-mg/kg
APOE ε4 carrier group [6]. Similar to the phase 2 studies,
most ARIA-E cases in the phase 3 studies occurred within
the first 3 doses (w39 weeks or 273 days) [6]. In a phase 1
study, two of eight patients treated with 200-mg ganteneru-
mab (every 4 weeks) developed ARIA-E after 2 or 4 doses
(every 4 weeks) [7].
A lower percentage of patients in the reanalysis of the ba-
pineuzumab phase 2 studies [3] had ARIA-H at baseline
(9.2%, 19 of 207) compared with our studies (18.8%). In
these studies, incident ARIA-H occurred in 24 of 294 patients
(8.1%) patients; however, treatment effect on incident ARIA-
H was not reported in this analysis. In the phase 3 bapineuzu-
mab studies, incident cerebral microhemorrhage and cerebral
hemosiderin deposition were only reported as serious
treatment-emergent adverse events at a much lower rate of
0.4% of APOE ε4 noncarriers and 0.7% of APOE ε4 carriers
treated with bapineuzumab (0.5% combined) compared with
0% of placebo-treated patients ([6], supplemental material).
Incident ARIA-H was similar between our studies (PBO,
7.3% and 9.1% SLZ) and the reanalyzed bapineuzumab
phase 2 studies (8.1%) [3]. Although statistical analysis of
treatment differences between placebo and bapineuzumab
[3] and placebo and gantenerumab [7] were not reported,
the treatment difference between placebo and solanezumab
for incident ARIA-H was not statistically significant.
A similar percentage of APOE ε4 allele carriers was seen
in solanezumab-treated patients with ARIA-E compared
with the overall trial population (58% vs 59%), suggesting
that the APOE ε4 allele is not overrepresented in the cohort
with ARIA-E. However, the percentage of homozygous
APOE ε4 patients with ARIA-E (32%) is higher than inthe overall study population (13%) suggesting that APOE
ε4 homozygotes have an increased risk of developing
ARIA-E. In patients with ARIA-E who had APOE genotyp-
ing in the retrospective review of the phase 2 bapineuzumab
trials, the APOE ε4 allele was present in 86% compared with
65% of the overall cohort [3]. Similar to the EXPEDITION
studies, a greater percentage of patients who developed
ARIA were APOE ε4 homozygotes compared with the per-
centage of APOE ε4 homozygotes in the overall trial popu-
lation (36% vs 16%, respectively) [3]. Using Cox
proportional hazards models, an increased risk of ARIA-E
was determined of approximately 3-4-fold and 7-fold in
APOE ε4 heterozygotes and homozygotes, respectively [3].
In the phase 3 bapineuzumab studies after central read of
the MRIs, ARIA-E was reported in APOE ε4 carriers at
1.1% in placebo-treated patients and 16.9%–34.5% in
bapineuzumab-treated patients and in noncarriers at 0.6%
and 5.6%–19.9% in placebo-treated and bapineuzumab-
treated patients, respectively [6]. In addition, the two patients
treated with 200-mg gantenerumab in the phase 1 study who
developed ARIA-E were homozygous for APOE ε4 [7].
Other data have suggested that APOE ε4 carriers have a
higher vascular amyloid burden [12–13] which could lead
to increased ARIA-H and/or vascular permeability [14].
Other data also suggest an interrelationship between
ARIA-H and ARIA-E as in many cases, new ARIA-H was
seen in the location of ARIA-E before it occurs or after it
has resolved [1,3]. In our studies, 71% (15 of 21) of patients
with ARIA-E and scans assessable for ARIA-H, experienced
increases in ARIA-H at the time of ARIA-E; 48% (10 of 21)
had colocalization of ARIA-H changes with ARIA-E. In the
retrospective review of the phase 2 bapineuzumab studies,
82% (14 of 17) of bapineuzumab-treated patients had co-
incident ARIA-H and ARIA-E, and 57% (8 of 14) of patients
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treated patients who developed ARIA-E also had coincident
ARIA-H [7]. Taken together, these data support a relationship
between incident ARIA-H and ARIA-E. However, interest-
ingly, the one patient in the EXPEDITION studies that had
two instances of ARIA-E (Patient B, one during PBO treat-
ment and one during SLZ treatment) had no detectable
ARIA-H at baseline and no detectable changes in ARIA-H
before ARIA-E or after resolution.
Important clinical issues of ARIA-E include management
of associated symptoms and withdrawal or continuation of
treatment during ARIA-E. In our trials, when ARIA-E was
detected, no intervention was performed beyond holding sol-
anezumab infusion, and although some patients had very long
time to resolution or the ARIA-E was ongoing at their last
study MRI, all patients remained asymptomatic. In the phase
2 study, 6 of 12 of the bapineuzumab-treated patients with
ARIA-E had symptoms of headache, confusion, vomiting,
and gait disturbance, with one patient requiring treatment
with steroids [5]. Some answers to whether patients can be
treated through asymptomatic ARIA-E may be obtained
from patients that continued treatment during very subtle
asymptomatic ARIA-E that was not initially recognized
and discovered only after retrospective review of MRIs. In
our trials, eight patients were dosed though ARIA-E (range
3 to 17 infusions) with no associated symptoms and a variable
outcome from complete resolution to increased severity at the
final MRI. In the bapineuzumab phase 2 and 3 trials, an
increased incidence of ARIA-Ewas discovered after rereview
by central readers [3,5]; these additionally identified ARIA-E
patients continued treatment while mild, asymptomatic
ARIA-E was present. Taken together, these data suggest
that the treatment may continue during the presence of mild
asymptomatic ARIA-E.
The ability to restart therapy after resolution of ARIA-E is
another important aspect of clinical management. Four pa-
tients with ARIA-E were treated with or re-challenged with
solanezumab after complete resolution of ARIA-E (range,
50–75 days) and 3 of 4 had no additional reoccurrence over
approximately 1–2 years additional exposure. In the phase
2 study, after resolution of ARIA-E, 6 bapineuzumab-
treated patients restarted treatment with 0.15 mg/kg and
were titrated up to 50% of the original dose without reoccur-
rence of ARIA-E [5]. However, two patients with ARIA-E
detected after the central reread in the bapineuzumab phase
2 studies developed ARIA-E again when re-challenged [3].
Preclinical animal models suggest that repair and remodeling
of cerebral vasculature occurs [15] after ARIA [16] that may
prevent further occurrence [17]. If similar mechanisms are
functioning after ARIA in humans, it would explain the abil-
ity to rechallenge patients without further occurrence of
ARIA-E with solanezumab or bapineuzumab in some pa-
tients [3,5] and the differential location of 2 instances of
ARIA-E in one patient in our trials.
One limitation of our data is the extent of follow-up after
ARIA-E due to the patients’ willingness or ability to returnfor unscheduled MRIs. Another limitation is that testing for
evidence of amyloid pathology was not a required inclusion
criterion for these studies. However, as ARIA is associated
with the presence of amyloid pathology, all patients who
developed ARIA are presumed to be amyloid positive. In
addition, only three patients in the ARIA-E cohort partici-
pated in the optional amyloid-PET addendum and only one
placebo patient had an endpoint PET scan, limiting the
assessment of correlation between location and amount of
amyloid plaque change and ARIA-E.
Although the presentation of ARIA-E is variable among
patients participating in clinical trials, when it occurs, it ap-
pears to be manageable with close monitoring, withholding
investigational therapy, treatment of any potential associated
symptoms and re-initiation of treatment. Additional data and
analyses will help to further guide clinicians in the manage-
ment of ARIA in their patients with AD.
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1. Systematic review: The authors searched available
literature using PubMed and OVID search engines
to identify articles. Meeting abstracts and presenta-
tions were also reviewed. The relationship between
immunotherapy and ARIA is not clear and may
depend on the class and Ab binding site of the anti-
body. The clinical aspects of ARIA have been
described and published or presented, and the rele-
vant references have been cited.
2. Interpretation: Our findings support others’ findings
on ARIA in the clinical trial setting; although it is
difficult to draw direct comparisons to other trials
because this level of individual patient detail is not
available.
3. Future directions: The article may help guide clini-
cians’ treatment decisions for individual patients
with AD with ARIA in clinical trials and in general
practice. Descriptions of individual cases highlight
the variable presentation and resolution of ARIA,
whereas summary information may guide a general
approach to management of this phenomenon.
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